April 26 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board:IAGX.ob – News) announced today that Celadrin®, the company’s flagship dietary supplement brand for joint health, will be sold at the nation’s leading retailer. Celadrin® continues to build its national distribution base in the mass market as well as its brand recognition. Now, both new and loyal [...]
{ 0 comments }
San Diego, CA *** November 4, 2009*** — Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix’s 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease. Commenting on the patent issuance, Mr. William P. Spencer, [...]
{ 0 comments }
Imagenetix Also Introduces New Ear, Nose and Throat Product – BioGuard(TM) – BioGuard(TM) Promotes Protection for the Entire Family SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News) announced that InflameAway Celadrin® extra strength soft gels for joint health are currently available at the nation’s number one drug chain, the [...]
{ Comments on this entry are closed }
Listen to the interview below. Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health, announced today that its Director of Research and Development, Dr. Robert Hesslink, discussed 1-TDC and periodontal disease on Bloomberg Radio. The company also recently announced the publication of [...]
{ Comments on this entry are closed }
SAN DIEGO, Aug. 13 /PRNewswire-FirstCall/ — On June 22, 2009, Cetyl Max/Flexadren mischaracterized certain facts associated with the settlement between those entities and Imagenetix (OTC Bulletin Board: IAGX – News). Both companies extend their apologies to Imagenetix and to those who may have been affected by the mischaracterization.
{ Comments on this entry are closed }